Stay updated on Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial
Sign up to get notified when there's something new on the Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial page.

Latest updates to the Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThis change is a minor revision update from v3.3.1 to v3.3.2 and does not modify the study data or parameters. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check22 days agoChange DetectedThe page adds a note that PubMed publications are auto-filled for the study and updates the page revision from v3.2.0 to v3.3.1.SummaryDifference0.1%

- Check29 days agoChange DetectedThe site-wide banner about government funding and NIH operating status on the page has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check44 days agoChange DetectedThe updates appear to be minor formatting and text edits on the Study Details page, with no changes to the primary outcomes, study design, enrollment, or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check72 days agoChange DetectedUpgrade to v3.2.0 with a new operating-status notice about government funding and a link to operating status details; removes v3.1.0 reference.SummaryDifference3%

- Check79 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial page.